NO923321L - Oligonukleotidterapi for aa modulere virkningene av herpesvirus - Google Patents
Oligonukleotidterapi for aa modulere virkningene av herpesvirusInfo
- Publication number
- NO923321L NO923321L NO92923321A NO923321A NO923321L NO 923321 L NO923321 L NO 923321L NO 92923321 A NO92923321 A NO 92923321A NO 923321 A NO923321 A NO 923321A NO 923321 L NO923321 L NO 923321L
- Authority
- NO
- Norway
- Prior art keywords
- herpesvirus
- methods
- herpes simplex
- specifically hybridizable
- simplex virus
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
- C12N15/1133—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against herpetoviridae, e.g. HSV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/312—Phosphonates
- C12N2310/3125—Methylphosphonates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/485,297 US5248670A (en) | 1990-02-26 | 1990-02-26 | Antisense oligonucleotides for inhibiting herpesviruses |
PCT/US1991/001327 WO1991012811A1 (en) | 1990-02-26 | 1991-02-25 | Oligonucleotide therapies for modulating the effects of herpesviruses |
Publications (2)
Publication Number | Publication Date |
---|---|
NO923321D0 NO923321D0 (no) | 1992-08-25 |
NO923321L true NO923321L (no) | 1992-08-25 |
Family
ID=23927618
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO92923321A NO923321L (no) | 1990-02-26 | 1992-08-25 | Oligonukleotidterapi for aa modulere virkningene av herpesvirus |
Country Status (14)
Country | Link |
---|---|
US (3) | US5248670A (fi) |
EP (1) | EP0517859B1 (fi) |
JP (1) | JP2795538B2 (fi) |
AT (1) | ATE168561T1 (fi) |
AU (1) | AU652152B2 (fi) |
BR (1) | BR9106087A (fi) |
CA (1) | CA2074523A1 (fi) |
DE (1) | DE69129848T2 (fi) |
DK (1) | DK0517859T3 (fi) |
ES (1) | ES2118082T3 (fi) |
FI (1) | FI923707A0 (fi) |
HU (1) | HUT64474A (fi) |
NO (1) | NO923321L (fi) |
WO (1) | WO1991012811A1 (fi) |
Families Citing this family (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5635488A (en) * | 1991-10-15 | 1997-06-03 | Isis Pharmaceuticals, Inc. | Compounds having phosphorodithioate linkages of high chiral purity |
US5620963A (en) * | 1991-10-15 | 1997-04-15 | Isis Pharmaceuticals, Inc. | Oligonucleotides for modulating protein kinase C having phosphorothioate linkages of high chiral purity |
US6339066B1 (en) | 1990-01-11 | 2002-01-15 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides which have phosphorothioate linkages of high chiral purity and which modulate βI, βII, γ, δ, Ε, ζ and η isoforms of human protein kinase C |
US5587361A (en) * | 1991-10-15 | 1996-12-24 | Isis Pharmaceuticals, Inc. | Oligonucleotides having phosphorothioate linkages of high chiral purity |
US5248670A (en) * | 1990-02-26 | 1993-09-28 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides for inhibiting herpesviruses |
US5514577A (en) * | 1990-02-26 | 1996-05-07 | Isis Pharmaceuticals, Inc. | Oligonucleotide therapies for modulating the effects of herpes viruses |
IL99172A (en) * | 1990-08-15 | 1999-03-12 | Genta Inc | Reverse oligonucleotides corresponding to gene B of the herpes simplex virus type 1 that are active as antiviral agents and their use |
AU649717B2 (en) * | 1990-08-16 | 1994-06-02 | Isis Pharmaceuticals, Inc. | Oligonucleotides for modulating the effects of cytomegalovirus infections |
US5359052A (en) * | 1991-08-05 | 1994-10-25 | Polish Academy Of Sciences | Chalcophospholanes useful in the synthesis of oligonucleoside phosphorothioates, phosphorodithioates and related selenates |
US5646267A (en) * | 1991-08-05 | 1997-07-08 | Polish Academy Of Sciences | Method of making oligonucleotides and oligonucleotide analogs using phospholanes and enantiomerically resolved phospholane analogues |
US7119184B2 (en) | 1991-08-12 | 2006-10-10 | Isis Pharmaceuticals, Inc. | Oligonucleotides having A-DNA form and B-DNA form conformational geometry |
US6369209B1 (en) | 1999-05-03 | 2002-04-09 | Isis Pharmaceuticals, Inc. | Oligonucleotides having A-DNA form and B-DNA form conformational geometry |
US5599797A (en) * | 1991-10-15 | 1997-02-04 | Isis Pharmaceuticals, Inc. | Oligonucleotides having phosphorothioate linkages of high chiral purity |
US5661134A (en) * | 1991-10-15 | 1997-08-26 | Isis Pharmaceuticals, Inc. | Oligonucleotides for modulating Ha-ras or Ki-ras having phosphorothioate linkages of high chiral purity |
US5607923A (en) * | 1991-10-15 | 1997-03-04 | Isis Pharmaceuticals, Inc. | Oligonucleotides for modulating cytomegalovirus having phosphorothioate linkages of high chiral purity |
US5654284A (en) * | 1991-10-15 | 1997-08-05 | Isis Pharmaceuticals, Inc. | Oligonucleotides for modulating RAF kinase having phosphorothioate linkages of high chiral purity |
US5576302A (en) * | 1991-10-15 | 1996-11-19 | Isis Pharmaceuticals, Inc. | Oligonucleotides for modulating hepatitis C virus having phosphorothioate linkages of high chiral purity |
AU3129993A (en) * | 1991-11-08 | 1993-06-07 | Massachusetts Institute Of Technology | Localized oligonucleotide therapy |
GB9125891D0 (en) * | 1991-12-05 | 1992-02-05 | Inst Of Cancer The Research | Antiviral agent |
US6537973B1 (en) | 1992-03-16 | 2003-03-25 | Isis Pharmaceuticals, Inc. | Oligonucleotide inhibition of protein kinase C |
EP0683668A4 (en) * | 1993-01-27 | 1997-12-29 | Affymax Tech Nv | PREPARATIONS AND METHODS FOR TRANSDERMAL DRUG ADMINISTRATION. |
US6824976B1 (en) * | 1993-04-02 | 2004-11-30 | Rigel Pharmaceuticals, Inc. | Method for selective inactivation of viral replication |
DE4331670A1 (de) * | 1993-09-17 | 1995-03-23 | Hoechst Ag | Neue Antisense-Oligonucleotide gegen HSV-1 sowie deren Herstellung |
US5550047A (en) * | 1994-02-18 | 1996-08-27 | University Of Massachusetts | Oligonucleotides with anti-Epstein-Barr virus activity |
US6727230B1 (en) | 1994-03-25 | 2004-04-27 | Coley Pharmaceutical Group, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
WO1995026204A1 (en) * | 1994-03-25 | 1995-10-05 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
US5801235A (en) * | 1994-05-25 | 1998-09-01 | Hybridon, Inc. | Oligonucleotides with anti-cytomegalovirus activity |
WO1996001050A1 (en) * | 1994-07-05 | 1996-01-18 | Baltech, Inc. | Prevention and treatment of human herpesvirus-6 infection with quaternary ammonium compounds and/or ganglionic blocking agents |
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
DE69535036T3 (de) | 1994-07-15 | 2011-07-07 | The University of Iowa Research Foundation, IA | Immunomodulatorische oligonukleotide |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US7935675B1 (en) | 1994-07-15 | 2011-05-03 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20030026782A1 (en) * | 1995-02-07 | 2003-02-06 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
WO1996003500A1 (fr) * | 1994-07-26 | 1996-02-08 | Ltt Institute Co., Ltd. | Substance a activite antivirale |
US6608035B1 (en) | 1994-10-25 | 2003-08-19 | Hybridon, Inc. | Method of down-regulating gene expression |
US5591721A (en) * | 1994-10-25 | 1997-01-07 | Hybridon, Inc. | Method of down-regulating gene expression |
US6645943B1 (en) | 1994-10-25 | 2003-11-11 | Hybridon, Inc. | Method of down-regulating gene expression |
US6667293B1 (en) | 1995-09-12 | 2003-12-23 | Hybridon, Inc. | Use of cyclodextrins to modulate gene expression with reduced immunostimulatory response |
US5837854A (en) * | 1996-04-05 | 1998-11-17 | University Of Massachusetts | Oligonucleotides with anti-Epstein-Barr virus activity |
US6111085A (en) | 1996-09-13 | 2000-08-29 | Isis Pharmaceuticals, Inc. | Carbamate-derivatized nucleosides and oligonucleosides |
EP0855184A1 (en) * | 1997-01-23 | 1998-07-29 | Grayson B. Dr. Lipford | Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination |
US6127533A (en) | 1997-02-14 | 2000-10-03 | Isis Pharmaceuticals, Inc. | 2'-O-aminooxy-modified oligonucleotides |
US6576752B1 (en) | 1997-02-14 | 2003-06-10 | Isis Pharmaceuticals, Inc. | Aminooxy functionalized oligomers |
US6172209B1 (en) | 1997-02-14 | 2001-01-09 | Isis Pharmaceuticals Inc. | Aminooxy-modified oligonucleotides and methods for making same |
US6214806B1 (en) | 1997-02-28 | 2001-04-10 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CPC dinucleotide in the treatment of LPS-associated disorders |
US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
CA2301575C (en) | 1997-05-20 | 2003-12-23 | Ottawa Civic Hospital Loeb Research Institute | Vectors and methods for immunization or therapeutic protocols |
US6610539B1 (en) * | 1997-07-10 | 2003-08-26 | Genesense Technologies, Inc. | Antisense oligonucleotide sequences as inhibitors of microorganisms |
AU760549B2 (en) | 1998-04-03 | 2003-05-15 | University Of Iowa Research Foundation, The | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
EP1674574A1 (en) * | 1998-05-14 | 2006-06-28 | Coley Pharmaceutical GmbH | Methods for Regulating Hematopoiesis using CpG-Oligonucleotides |
WO1999060167A1 (en) | 1998-05-21 | 1999-11-25 | Isis Pharmaceuticals, Inc. | Compositions and methods for topical delivery of oligonucleotides |
WO1999061056A2 (en) | 1998-05-22 | 1999-12-02 | Loeb Health Research Institute At The Ottawa Hospital | Methods and products for inducing mucosal immunity |
US20030022854A1 (en) | 1998-06-25 | 2003-01-30 | Dow Steven W. | Vaccines using nucleic acid-lipid complexes |
US6242589B1 (en) | 1998-07-14 | 2001-06-05 | Isis Pharmaceuticals, Inc. | Phosphorothioate oligonucleotides having modified internucleoside linkages |
US6867294B1 (en) | 1998-07-14 | 2005-03-15 | Isis Pharmaceuticals, Inc. | Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages |
US6277967B1 (en) | 1998-07-14 | 2001-08-21 | Isis Pharmaceuticals, Inc. | Carbohydrate or 2′-modified oligonucleotides having alternating internucleoside linkages |
US6077709A (en) | 1998-09-29 | 2000-06-20 | Isis Pharmaceuticals Inc. | Antisense modulation of Survivin expression |
US6335194B1 (en) | 1998-09-29 | 2002-01-01 | Isis Pharmaceuticals, Inc. | Antisense modulation of survivin expression |
US6492111B1 (en) * | 1998-11-25 | 2002-12-10 | Isis Pharmaceuticals, Inc. | In situ binary synthesis of biologically effective molecules |
EP1152009B2 (en) | 1999-02-12 | 2017-09-06 | Daiichi Sankyo Company, Limited | Novel nucleosides and oligonucleotide analogues |
US6977245B2 (en) * | 1999-04-12 | 2005-12-20 | The United States Of America As Represented By The Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
JP4151751B2 (ja) * | 1999-07-22 | 2008-09-17 | 第一三共株式会社 | 新規ビシクロヌクレオシド類縁体 |
US6147200A (en) * | 1999-08-19 | 2000-11-14 | Isis Pharmaceuticals, Inc. | 2'-O-acetamido modified monomers and oligomers |
US6949520B1 (en) | 1999-09-27 | 2005-09-27 | Coley Pharmaceutical Group, Inc. | Methods related to immunostimulatory nucleic acid-induced interferon |
ATE378348T1 (de) * | 2000-01-14 | 2007-11-15 | Us Health | Oligodeoxynukleotide und ihre verwendung zur induktion einer immunreaktion |
US7585847B2 (en) | 2000-02-03 | 2009-09-08 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for the treatment of asthma and allergy |
AU2001270134B2 (en) | 2000-06-22 | 2006-06-15 | University Of Iowa Research Foundation | Methods for enhancing antibody-induced cell lysis and treating cancer |
CN1274072C (zh) * | 2000-08-03 | 2006-09-06 | 松下电器产业株式会社 | 无刷电机及其制造方法 |
US6818787B2 (en) * | 2001-06-11 | 2004-11-16 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
US7666674B2 (en) | 2001-07-27 | 2010-02-23 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo |
AU2002361468A1 (en) | 2001-08-14 | 2003-03-18 | The Government Of The United States Of America As Represented By The Secretary Of Health And Human S | Method for rapid generation of mature dendritic cells |
PT1446162E (pt) | 2001-08-17 | 2009-01-27 | Coley Pharm Gmbh | Agrupamentos imunoestimuladores oligonucléotidos com actividade melhorada |
US8466116B2 (en) | 2001-12-20 | 2013-06-18 | The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of CpG oligodeoxynucleotides to induce epithelial cell growth |
AU2002366710A1 (en) | 2001-12-20 | 2003-07-09 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of | USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS |
EA008940B1 (ru) | 2002-09-13 | 2007-10-26 | Репликор, Инк. | Антивирусные олигонуклеотиды, не связанные с комплементарностью последовательностей |
US20050196382A1 (en) * | 2002-09-13 | 2005-09-08 | Replicor, Inc. | Antiviral oligonucleotides targeting viral families |
US8263091B2 (en) | 2002-09-18 | 2012-09-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides |
PT2241325E (pt) | 2002-10-29 | 2012-04-12 | Coley Pharm Gmbh | Utilização de oligonucleótidos cpg no tratamento de infecção com vírus da hepatite c |
AU2003300919A1 (en) | 2002-12-11 | 2004-06-30 | Coley Pharmaceutical Gmbh | 5' cpg nucleic acids and methods of use |
JP4503590B2 (ja) † | 2003-02-10 | 2010-07-14 | サンタリス ファーマ アー/エス | サバイビン発現を調整するためのオリゴマー化合物 |
US7713738B2 (en) * | 2003-02-10 | 2010-05-11 | Enzon Pharmaceuticals, Inc. | Oligomeric compounds for the modulation of survivin expression |
US20090215860A1 (en) * | 2004-06-17 | 2009-08-27 | The Regents Of The University Of California | Compositions and methods for regulating gene transcription |
US20060154888A1 (en) * | 2004-11-09 | 2006-07-13 | Santaris Pharma A/S | LNA oligonucleotides and the treatment of cancer |
WO2006133099A2 (en) * | 2005-06-03 | 2006-12-14 | The Cbr Institute For Biomedical Research, Inc. | Sirna microbicides for preventing and treating viral diseases |
US20070141559A1 (en) * | 2005-12-20 | 2007-06-21 | Quest Diagnostics Inc | Methods for detecting and typing herpes simplex virus |
US10799523B2 (en) | 2015-02-04 | 2020-10-13 | F. Hoffmann-La Roche Ag | Tau antisense oligomers and uses thereof |
EP3954993A1 (en) | 2015-02-04 | 2022-02-16 | Bristol-Myers Squibb Company | Methods of selecting therapeutic molecules |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4757055A (en) * | 1980-11-12 | 1988-07-12 | The Johns Hopkins University | Method for selectively controlling unwanted expression or function of foreign nucleic acids in animal or mammalian cells |
NZ209840A (en) * | 1983-10-17 | 1988-11-29 | Kaji Akira | A method of inhibiting viral propagation by hybridising dna with the viral rna thus blocking its action |
US4806463A (en) * | 1986-05-23 | 1989-02-21 | Worcester Foundation For Experimental Biology | Inhibition of HTLV-III by exogenous oligonucleotides |
US5110802A (en) * | 1987-07-14 | 1992-05-05 | City Of Hope | Oligonucleotide phosphonates and method of inhibiting a human immunodeficiency virus in vitro utilizing said oligonucleotide phosphonates |
US5004810A (en) * | 1988-09-30 | 1991-04-02 | Schering Corporation | Antiviral oligomers |
US5248670A (en) * | 1990-02-26 | 1993-09-28 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides for inhibiting herpesviruses |
US5166195A (en) * | 1990-05-11 | 1992-11-24 | Isis Pharmaceuticals, Inc. | Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides |
-
1990
- 1990-02-26 US US07/485,297 patent/US5248670A/en not_active Expired - Lifetime
-
1991
- 1991-02-25 CA CA002074523A patent/CA2074523A1/en not_active Abandoned
- 1991-02-25 DE DE69129848T patent/DE69129848T2/de not_active Expired - Fee Related
- 1991-02-25 ES ES91908334T patent/ES2118082T3/es not_active Expired - Lifetime
- 1991-02-25 HU HU9202746A patent/HUT64474A/hu unknown
- 1991-02-25 US US07/852,132 patent/US6310044B1/en not_active Expired - Fee Related
- 1991-02-25 AT AT91908334T patent/ATE168561T1/de not_active IP Right Cessation
- 1991-02-25 AU AU77470/91A patent/AU652152B2/en not_active Ceased
- 1991-02-25 WO PCT/US1991/001327 patent/WO1991012811A1/en active IP Right Grant
- 1991-02-25 DK DK91908334T patent/DK0517859T3/da active
- 1991-02-25 BR BR919106087A patent/BR9106087A/pt not_active Application Discontinuation
- 1991-02-25 JP JP3507979A patent/JP2795538B2/ja not_active Expired - Fee Related
- 1991-02-25 EP EP91908334A patent/EP0517859B1/en not_active Expired - Lifetime
-
1992
- 1992-08-18 FI FI923707A patent/FI923707A0/fi not_active Application Discontinuation
- 1992-08-25 NO NO92923321A patent/NO923321L/no unknown
-
1994
- 1994-10-26 US US08/329,212 patent/US5658891A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
DE69129848T2 (de) | 1999-04-29 |
EP0517859A1 (en) | 1992-12-16 |
ES2118082T3 (es) | 1998-09-16 |
WO1991012811A1 (en) | 1991-09-05 |
NO923321D0 (no) | 1992-08-25 |
JP2795538B2 (ja) | 1998-09-10 |
AU652152B2 (en) | 1994-08-18 |
HUT64474A (en) | 1994-01-28 |
EP0517859B1 (en) | 1998-07-22 |
US5248670A (en) | 1993-09-28 |
AU7747091A (en) | 1991-09-18 |
DK0517859T3 (da) | 1998-12-14 |
BR9106087A (pt) | 1993-02-02 |
US6310044B1 (en) | 2001-10-30 |
JPH05503016A (ja) | 1993-05-27 |
US5658891A (en) | 1997-08-19 |
ATE168561T1 (de) | 1998-08-15 |
FI923707A (fi) | 1992-08-18 |
DE69129848D1 (de) | 1998-08-27 |
FI923707A0 (fi) | 1992-08-18 |
CA2074523A1 (en) | 1991-08-27 |
EP0517859A4 (en) | 1993-08-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO923321D0 (no) | Oligonukleotidterapi for aa modulere virkningene av herpesvirus | |
EP0692930A4 (en) | OLIGONUCLEOTIDE TREATMENTS FOR MODULATING THE EFFECTS OF HERPESVIRUS | |
Rock et al. | Detection of latency-related viral RNAs in trigeminal ganglia of rabbits latently infected with herpes simplex virus type 1 | |
Slater et al. | The trigeminal ganglion is a location for equine herpesvirus 1 latency and reactivation in the horse | |
Efstathiou et al. | Detection of herpes simplex virus-specific DNA sequences in latently infected mice and in humans | |
Perng et al. | The latency-associated transcript gene of herpes simplex virus type 1 (HSV-1) is required for efficient in vivo spontaneous reactivation of HSV-1 from latency | |
Kennedy | Varicella‐zoster virus latency in human ganglia | |
Ramakrishnan et al. | PCR-based analysis of herpes simplex virus type 1 latency in the rat trigeminal ganglion established with a ribonucleotide reductase-deficient mutant | |
HU9300398D0 (en) | Oligo-nucleotides influencing effect of infection by cyto-megalo virus | |
Ecob-Prince et al. | Reactivation in vivo and in vitro of herpes simplex virus from mouse dorsal root ganglia which contain different levels of latency-associated transcripts | |
Stevens | Overview of herpesvirus latency | |
Doerig et al. | Detection of the latency-associated transcript in neuronal cultures during the latent infection with herpes simplex virus type 1 | |
Spivack et al. | Replication, establishment of latent infection, expression of the latency-associated transcripts and explant reactivation of herpes simplex virus type 1 γ 34.5 mutants in a mouse eye model | |
Kennedy et al. | A molecular and cellular model to explain the differences in reactivation from latency by herpes simplex and varicella–zoster viruses | |
Becker et al. | PCR detection of amplified 132 bp repeats in Marek's disease virus type 1 (MDV-1) DNA can serve as an indicator for critical genomic rearrangement leading to the attenuation of virus virulence | |
Tenser et al. | Latent herpesvirus infections of neurons in guinea pigs and humans. | |
Hay et al. | Varicella zoster virus—a different kind of herpesvirus latency? | |
Hilleman | Herpes simplex vaccines | |
Zhang et al. | Transcriptional regulation of latency-associated transcripts (LATs) of herpes simplex viruses | |
KR937000116A (ko) | 헤르페스바이러스의 효과를 조절하기 위한 올리고뉴클레오티드 요법 | |
Wirth | Comparison of immediate-early transcripts among bovine herpesvirus type 1 and type 5 strains differing in neurovirulent potential | |
Pari et al. | Effect of human cytomegalovirus on replication of SV40 origin and the expression of T antigen | |
Stevens | Transcripts associated with herpes simplex virus latency | |
Scheck et al. | Transcriptional activity of the herpes simplex virus genome during establishment, maintenance, and reactivation of in vitro virus latency | |
Jun et al. | The UL4 gene of herpes simplex virus type 1 is dispensable for latency, reactivation and pathogenesis in mice. |